Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a year-to-date increase of 43.25% and a recent uptick of 2.37% on October 23, 2023, indicating strong market interest and performance [1]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the early stages of new drug development, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a 41.60% increase compared to the previous period [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - The top circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Agricultural Bank Medical Health Stock, with changes in their holdings indicating active institutional interest [3].

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a 43.27% increase, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the early stages of new drug development, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, up 41.60% year-on-year [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which is the second-largest shareholder with 4.2526 million shares, and Agricultural Bank of China Medical Health Stock, which increased its holdings by 17.75% [2].

Company Overview - Bid Pharma's stock increased by 5.2%, reaching 68.14 CNY per share, with a trading volume of 16.89 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 6.193 billion CNY [1] - The company, established on April 27, 2007, and listed on October 11, 2022, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Fund Holdings - According to data, one fund under Xinda Australia, the Xinao Small and Medium Cap Mixed A (610004), holds a significant position in Bid Pharma, with 227,200 shares, accounting for 6.11% of the fund's net value, making it the fourth-largest holding [2] - The fund has achieved a floating profit of approximately 765,800 CNY today [2] - The Xinao Small and Medium Cap Mixed A fund was established on December 1, 2009, with a current size of 216 million CNY, yielding 22.89% year-to-date and ranking 3,418 out of 8,234 in its category [2] Fund Manager Performance - The fund manager, Zeng Guofu, has a tenure of 17 years and 87 days, with a total fund size of 481 million CNY, achieving a best return of 109.1% and a worst return of -57.43% during his tenure [3] - Co-manager Li Diandian has been in position for 1 year and 6 days, managing a fund size of 570 million CNY, with a best return of 35.83% and a worst return of 14.26% during his tenure [3]

Core Points - Bid Pharma's stock price decreased by 10.07% this week, closing at 64.77 yuan, with a market capitalization of 5.886 billion yuan [1] - The company plans to conduct foreign exchange hedging to mitigate currency fluctuation risks, with a maximum contract value of 600 million yuan [2][4] - Bid Pharma's initial public offering raised approximately 1.335 billion yuan, with plans to use up to 200 million yuan of idle funds for cash management [3][4] Company Announcements - Bid Pharma intends to engage in foreign exchange hedging, with a limit of 600 million yuan for any single trading day [2][4] - The company has approved the use of up to 200 million yuan of idle raised funds for cash management, focusing on low-risk, liquid financial products [3][4]

Group 1 - The core point of the news is that Shanghai Bid Pharmaceutical Co., Ltd. is taking measures to manage foreign exchange risks and optimize the use of idle funds from its initial public offering [1][2][3] Group 2 - On October 16, 2023, Bid Pharmaceutical's stock closed at 66.4 yuan, down 3.02%, with a turnover rate of 1.99% and a trading volume of 8,585 lots, amounting to 58.1291 million yuan [1] - The main capital flow on October 16 showed a net outflow of 184,400 yuan from institutional investors, accounting for 0.32% of the total trading volume, while retail investors had a net outflow of 1.066 million yuan, representing 1.83% of the total [1][3] - The company plans to conduct foreign exchange hedging activities with a maximum contract value of 600 million yuan, using its own funds, and has established a foreign exchange risk management system [1][3] - The company intends to use up to 200 million yuan of temporarily idle raised funds for cash management, investing in low-risk, liquid, and principal-protected financial products [2][3]

Core Viewpoint - Bid Pharma (688073) is actively managing its financial risks through foreign exchange hedging and optimizing the use of idle funds from its IPO, which reflects a strategic approach to enhance financial stability and operational efficiency [1][2][3] Trading Information Summary - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up by 3.66%, with a turnover rate of 1.71%, a trading volume of 7,414 shares, and a transaction value of 50.07 million CNY [1] - On the same day, the net inflow of main funds was 28.05 thousand CNY, accounting for 0.56% of the total transaction value, while retail investors saw a net inflow of 721.24 thousand CNY, representing 14.4% of the total [1] Company Announcements Summary - Bid Pharma plans to conduct foreign exchange hedging to mitigate currency fluctuation risks due to its import and export operations, with a maximum contract value of 600 million CNY and a margin and premium not exceeding 20 million CNY, funded by its own resources [1] - The company has established a foreign exchange risk management system and has received approval from its board for this hedging activity, which is valid for 12 months [1] - Additionally, Bid Pharma intends to utilize up to 200 million CNY of temporarily idle funds from its IPO for cash management, focusing on safe, liquid, and short-term investment products [2] - This cash management plan has also been approved by the company's board and is expected to enhance the efficiency of fund utilization without affecting the ongoing investment projects [2]

Core Viewpoint - Bid Pharma (688073) is implementing foreign exchange hedging to mitigate currency fluctuation risks due to its import and export business primarily settled in foreign currencies [1] Group 1: Stock Performance - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up 3.66% from the previous trading day, with a total market capitalization of 6.223 billion CNY [1] - The stock opened at 66.05 CNY, reached a high of 68.64 CNY, and a low of 65.21 CNY, with a trading volume of 50.0698 million CNY and a turnover rate of 1.71% [1] Group 2: Foreign Exchange Hedging Business - The company plans to conduct foreign exchange hedging with a maximum contract value of 600 million CNY on any trading day, and the margin and premium will not exceed 20 million CNY [1] - The hedging transactions will involve currencies such as USD, EUR, GBP, and HKD, utilizing methods including spot foreign exchange, forward foreign exchange, swaps, and options [1] - The board of directors has authorized the chairman or designated personnel to sign relevant documents within the approved limits, effective for 12 months from the board's approval [1] - The company has established a foreign exchange risk management system and implemented multiple risk control measures [1] - The matter has been approved by the 25th meeting of the second board of directors and does not require submission to the shareholders' meeting for approval [1] - The sponsor institution, Guotai Junan Securities, has no objections to the company's foreign exchange hedging business [1]

证券代码：688073 证券简称：毕得医药 公告编号：2025-083 上海毕得医药科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 万元 20,000 | | --- | --- | | 投资种类 | 安全性高、流动性好、满足保本要求的投资产品（包 | | | 括但不限于协定性存款、结构性存款、定期存款、大 | | | 额存单等产品） | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 上海毕得医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日召开第二届董事会第二十五次会议，第二届审计委员会第十次会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意董事会授权 董事长在上述额度范围内行使投资决策权并签署相关合同文件，公司财务总监 负责组织实施，公司财务管理部具体操作落实。 特别风险提示 公司使用最高额度不超过 2 亿元人民币暂时闲置募集资金进行现金管理， 为提高闲置募 ...

关于上海毕得医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上海毕 得医药科技股份有限公司（以下简称"毕得医药"、"公司"或"发行人"）首次公开 发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律法规和规范 性文件的要求，就毕得医药使用部分暂时闲置募集资金进行现金管理的事项进行 了审慎核查，并发表如下核查意见： 一、募集资金基本情况 国泰海通证券股份有限公司 | | | 1 | 1 | 药物分子砌块区域中心项目 | 28,000.00 | 28,000.00 | | --- | --- | --- | --- | | 2 | 研发实验室项目 | 7,435.61 | 7,435.61 | | 3 | 补充流动资金 | 8,000.00 | 8,000.00 | | | 合计 | 43,435.61 | 43,435.61 | 由于募投项目建设需要一定的周期，根据募投 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 开展外汇套期保值业务的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或者"保荐机构"）作为上 海毕得医药科技股份有限公司（以下简称"公司"、"毕得医药"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关法律法规和规范性文件的要求，对公司计划开展 外汇套期保值业务的事项进行了核查，具体情况如下： （二）资金来源 1 资金来源为自有资金，不涉及募集资金。 二、拟开展的外汇套期保值业务概述 （一）交易金额 公司及控股子公司拟开展的外汇套期保值业务资金额度为：任一交易日持有 的最高合约价值不超过 6 亿元人民币或其他等值货币，预计动用的交易保证金和 权力金任一交易日不超过 2,000 万元人民币或其他等值货币。开展期限内任一时 点的交易金额（含前述外汇套期保值业务的收益进行再交易的相关金额）不超过 前述额度范围。 一、开展外汇套期保值业务的背景及目的 公司及控股子公司进出口业务主要采用美元等外币进行结算，因 ...